Abiomed Inc (ABMD.OQ) News| Reuters.com
Edition:
United States

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

105.30USD
12:46pm EDT
Change (% chg)

$4.07 (+4.02%)
Prev Close
$101.23
Open
$101.94
Day's High
$105.31
Day's Low
$101.25
Volume
84,995
Avg. Vol
228,665
52-wk High
$110.63
52-wk Low
$64.07

Select another date:

Tue, May 3 2016

BRIEF-Abiomed reports Q4 GAAP earnings per share $0.24

* Abiomed announces Q4 FY 2016 revenue of $94.0 million, up 39% over prior year

BRIEF-Abiomed posts Q4 earnings per share $0.24

* Abiomed announces Q4 FY 2016 revenue of $94.0 million, up 39 pct over prior year

FDA approves Abiomed's device to treat cardiac shocks

The U.S Food and Drug Administration approved Abiomed Inc's heart pump to treat patients who suffer cardiac shock after heart attack or heart surgery, sending its shares up about 4 percent in extended trading.

FDA approves Abiomed's device to treat cardiac shocks

April 7 The U.S Food and Drug Administration approved Abiomed Inc's heart pump to treat patients who suffer cardiac shock after heart attack or heart surgery, sending its shares up about 4 percent in extended trading.

BRIEF-Abiomed Impella therapy receives FDA approval

* Abiomed impella therapy receives fda approval for cardiogenic shock after heart attack or heart surgery

BRIEF-Abiomed does not anticipate FDA advisory panel prior to PMA approval

* Co, FDA agreed on indication for use for pre-market approval ('PMA') for Impella 2.5, Impella CP, Impella 5.0 and Impella LD devices

Select another date: